BRPI0922937A2 - inibidores de pirrolopirazinil uréia quinase - Google Patents

inibidores de pirrolopirazinil uréia quinase

Info

Publication number
BRPI0922937A2
BRPI0922937A2 BRPI0922937A BRPI0922937A BRPI0922937A2 BR PI0922937 A2 BRPI0922937 A2 BR PI0922937A2 BR PI0922937 A BRPI0922937 A BR PI0922937A BR PI0922937 A BRPI0922937 A BR PI0922937A BR PI0922937 A2 BRPI0922937 A2 BR PI0922937A2
Authority
BR
Brazil
Prior art keywords
kinase inhibitors
pyrrolopyrazinyl
urea kinase
pyrrolopyrazinyl urea
inhibitors
Prior art date
Application number
BRPI0922937A
Other languages
English (en)
Inventor
Timothy Bamberg Joe
Cornelius Hermann Johannes
Soth Michael
Lemoine Remy
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0922937A2 publication Critical patent/BRPI0922937A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0922937A 2008-12-05 2009-11-26 inibidores de pirrolopirazinil uréia quinase BRPI0922937A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20100808P 2008-12-05 2008-12-05
US24417409P 2009-09-21 2009-09-21
PCT/EP2009/065878 WO2010063634A1 (en) 2008-12-05 2009-11-26 Pyrrolopyrazinyl urea kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI0922937A2 true BRPI0922937A2 (pt) 2019-09-24

Family

ID=41531848

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922937A BRPI0922937A2 (pt) 2008-12-05 2009-11-26 inibidores de pirrolopirazinil uréia quinase

Country Status (15)

Country Link
US (1) US8012974B2 (pt)
EP (1) EP2373653B1 (pt)
JP (1) JP5431495B2 (pt)
KR (1) KR101361858B1 (pt)
CN (1) CN102232076B (pt)
AR (1) AR074459A1 (pt)
AU (1) AU2009324210A1 (pt)
BR (1) BRPI0922937A2 (pt)
CA (1) CA2744507A1 (pt)
ES (1) ES2464458T3 (pt)
IL (1) IL212499A (pt)
MX (1) MX2011005597A (pt)
SG (1) SG171956A1 (pt)
TW (1) TWI403513B (pt)
WO (1) WO2010063634A1 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011004953A (es) 2008-11-10 2011-12-14 Vertex Pharma Compuestos utiles como inhibidores de cinasa atr.
ES2921576T3 (es) 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
RU2538204C2 (ru) * 2009-09-10 2015-01-10 Ф.Хоффманн-Ля Рош Аг Ингибиторы jak
WO2011143419A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated Pyrazines useful as inhibitors of atr kinase
NZ603478A (en) 2010-05-12 2014-09-26 Vertex Pharma 2 -aminopyridine derivatives useful as inhibitors of atr kinase
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2569286B1 (en) 2010-05-12 2014-08-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
EP2569313A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8969356B2 (en) 2010-05-12 2015-03-03 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2585468A1 (en) 2010-06-23 2013-05-01 Vertex Pharmaceuticals Incorporated Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
BR112012033402A2 (pt) 2010-07-02 2017-01-24 Gilead Sciences Inc moduladores de canais de íons conforme os compostos heterocíclicos fundidos
WO2012129491A1 (en) 2011-03-24 2012-09-27 Abbott Laboratories Trpv3 modulators
UY33966A (es) * 2011-03-25 2012-10-31 Abbott Lab Antagonistas del receptor transitorio potencial de vanilloides 1 (trpv1)
AU2012240030A1 (en) 2011-04-05 2013-10-24 Vertex Pharmaceuticals Incorporated Aminopyrazine compounds useful as inhibitors of TRA kinase
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
WO2012178123A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2723747A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
NO3175985T3 (pt) 2011-07-01 2018-04-28
WO2013049720A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP3878851A1 (en) 2011-09-30 2021-09-15 Vertex Pharmaceuticals Incorporated Process for making compounds useful as inhibitors of atr kinase
CA2850564A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
RU2018108589A (ru) 2011-09-30 2019-02-25 Вертекс Фармасьютикалз Инкорпорейтед Лечение рака поджелудочной железы и немелкоклеточного рака легкого ингибиторами atr
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2776420A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Pyrazine compounds useful as inhibitors of atr kinase
JP2015502925A (ja) 2011-11-09 2015-01-29 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Atrキナーゼの阻害剤として有用なピラジン化合物
EP2776429A1 (en) 2011-11-09 2014-09-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2013071090A1 (en) 2011-11-09 2013-05-16 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
PT2833973T (pt) 2012-04-05 2017-12-21 Vertex Pharma Compostos úteis como inibidores da cinase atr e terapias de combinação dos mesmos
IN2015MN00002A (pt) 2012-07-09 2015-10-16 Lupin Ltd
WO2014055756A1 (en) 2012-10-04 2014-04-10 Vertex Pharmaceuticals Incorporated Method for measuring atr inhibition mediated increases in dna damage
EP2909202A1 (en) 2012-10-16 2015-08-26 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2014089379A1 (en) 2012-12-07 2014-06-12 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US9663519B2 (en) 2013-03-15 2017-05-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9206188B2 (en) 2013-04-18 2015-12-08 Arrien Pharmaceuticals Llc Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
WO2015083028A1 (en) 2013-12-05 2015-06-11 Pfizer Inc. Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides
WO2015085132A1 (en) 2013-12-06 2015-06-11 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
HRP20200186T1 (hr) 2014-06-05 2020-05-29 Vertex Pharmaceuticals Inc. Radioaktivno obilježeni derivati 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-karboksamid spojeva koji se koriste kao inhibitori atr kinaze, priprava navedenih spojeva i njihovi različiti čvrsti oblici
JP6936007B2 (ja) 2014-06-17 2021-09-15 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Chk1阻害剤とatr阻害剤との組み合わせを使用してがんを処置する方法
EP3355926B1 (en) 2015-09-30 2025-12-24 Vertex Pharmaceuticals Inc. Combination of dna damaging agents and atr inhibitors for use in a method for treating cancer using
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110028469B (zh) * 2019-04-28 2022-08-09 南京药石科技股份有限公司 一种非阿片类镇痛药的关键中间体的制备方法及应用
KR102411479B1 (ko) * 2019-06-05 2022-06-22 공주대학교 산학협력단 벤즈아마이드 유도체 화합물 및 우레아제 억제제로서의 용도
KR102446237B1 (ko) * 2019-06-26 2022-09-21 공주대학교 산학협력단 인돌계 옥사디아졸 유도체, 이의 제조방법 및 이의 용도
WO2025231340A1 (en) * 2024-05-03 2025-11-06 Xenon Pharmaceuticals Inc. Azaindole and azaindoline compounds and uses thereof
WO2025231323A1 (en) * 2024-05-03 2025-11-06 Xenon Pharmaceuticals Inc. Bicyclic heteroaryl compounds and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9930698D0 (en) * 1999-12-24 2000-02-16 Rhone Poulenc Rorer Ltd Chemical compounds
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
EP1814883A1 (en) * 2004-11-22 2007-08-08 Vertex Pharmaceuticals Incorporated Bicyclic inhibitors or rho kinase
MX2007014377A (es) * 2005-05-17 2008-02-06 Plexxikon Inc Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina.
WO2007015866A2 (en) * 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
WO2008119792A1 (en) * 2007-04-02 2008-10-09 Palau Pharma, S. A. Pyrrolopyrimidine derivatives as jak3 inhibitors
PT2250172E (pt) 2008-02-25 2011-11-30 Hoffmann La Roche Inibidores de pirrolpirazina-cinase

Also Published As

Publication number Publication date
CA2744507A1 (en) 2010-06-10
SG171956A1 (en) 2011-07-28
KR101361858B1 (ko) 2014-02-12
EP2373653B1 (en) 2014-04-02
JP2012510972A (ja) 2012-05-17
AR074459A1 (es) 2011-01-19
CN102232076A (zh) 2011-11-02
CN102232076B (zh) 2014-12-31
KR20110079918A (ko) 2011-07-11
TW201033210A (en) 2010-09-16
JP5431495B2 (ja) 2014-03-05
EP2373653A1 (en) 2011-10-12
WO2010063634A1 (en) 2010-06-10
MX2011005597A (es) 2011-06-16
US8012974B2 (en) 2011-09-06
ES2464458T3 (es) 2014-06-02
TWI403513B (zh) 2013-08-01
AU2009324210A1 (en) 2010-06-10
US20100144745A1 (en) 2010-06-10
IL212499A0 (en) 2011-06-30
IL212499A (en) 2013-11-28

Similar Documents

Publication Publication Date Title
BRPI0922937A2 (pt) inibidores de pirrolopirazinil uréia quinase
CY2020024I1 (el) Αναστολεiς βητα-λακταμασων
BRPI0908494A2 (pt) Inibidores de pirrolopirazina quinase
BRPI0920135A2 (pt) imidazopiridazinacarbonitrilos úteis como inibidores de quinase
ATE519763T1 (de) Pyrrolopyrazin-kinasehemmer
BRPI0918846A2 (pt) inibidores de cinase heterocíclica
CY2017016I1 (el) Αναστολεις πρωτεασωματος
BRPI0913879A2 (pt) fenilpirazinonas como inibidores de quinase
BRPI0922880A2 (pt) compostos inibidores de quinase
BRPI0910668A2 (pt) inibidores de proteína quinases
EP2305306A4 (en) NEURO INVASION INHIBITOR
BRPI0814797A2 (pt) Inibidores dna-pk
BRPI1011129A2 (pt) métodos e compostos inibidores de janus cinase
BRPI0917808A2 (pt) inibidores de cmet
BRPI0912668A2 (pt) composto e composições como inibidores de quinase
BRPI0820544A2 (pt) 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase
BRPI0914652A2 (pt) compostos e composições como inibidores de quinase
EP2498607A4 (en) Kinase Inhibitors
EP2493313A4 (en) Kinase Inhibitors
BRPI0918564A2 (pt) inibidores
EP2558099A4 (en) Kinase inhibitors
BRPI0912475A2 (pt) compostos como inibidores de quinase
BRPI0906838A2 (pt) Pirimidinas como inibidores de quinase
IL218114A0 (en) 5-6-bicyclic heteroaryl-cotaining urea compounds as kinase inhibitors
BRPI0910979A2 (pt) compostos e composições como inibidores de quinase

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.